Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Investor Relations

Latest Financial Results

Q3 2018

Quarter Ended Sep 30, 2018

Stock Information

Nasdaq

MBRX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

Contact Information

Investor Relations
Lytham Partners, LLC
Joe Dorame
Managing Partner
T: (602) 889-9700

Transfer Agent
VStock Transfer, LLC

Auditor
Grant Thornton LLP

Legal Counsel
Schiff Hardin LLP
Cavas Pavri